By Zoey Becker The FDA rebuked Pfizer CEO Albert Bourla’s proposed solution to reports that some patients experienced a relapse of COVID-19 symptoms after treatment with the company's antiviral Paxlovid. After reports said some patients who took Paxlovid rebounded and...
Recently, an international trial site network known as the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) completed a global study revealing that remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2...
TFF Pharmaceuticals announced it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other respiratory viral diseases. TFF develops...
Paxlovid, the oral Pfizer treatment for COVID-19, appears headed for emergency use authorization in Europe. Conditional Marketing Authorization for Paxlovid The European Medical Agency’s (EMA) human medicines committee (CHMP) recommended Pfizer Europe MA EEIG...
BY MONIQUE BEALS Medicines Patent Pool, an organization supported by the U.N., announced on Thursday that over two dozen generic drug makers will soon begin producing Merck's COVID-19 pill to make the treatment more accessible in developing...
A research team led by Professor Hongzhe Sun, Norman & Cecilia Yip Professor in Bioinorganic Chemistry from the Department of Chemistry, Faculty of Science, the University of Hong Kong (HKU), in collaboration with Dr. Shuofeng Yuan, Assistant Professor from the...
New variants will pose continued threat, NIAID chief warns By John Bowden, Megan Sheets Dr Anthony Fauci warned at a Senate committee hearing that the US faced an “urgent need” for a so-called super vaccine that would be more effective at preventing new variants of...
By INSTITUT PASTEUR The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant within a few weeks or months. Initial epidemiological studies show that the...
— No reduced risk of mechanical ventilation or death by Zaina Hamza Colchicine (Colcrys) didn't benefit patients hospitalized with moderate to severe COVID-19-related pneumonia, researchers found in the COLCOVID randomized trial. Among more than 1,200 COVID-19...
— Group of physician-scientists believes data support authorization for treating COVID-19 by Sophie Putka t took about 4 days for David Boulware, MD, MPH, to write the FDA emergency use authorization (EUA) application for fluvoxamine. Yes, a doctor wrote an EUA...
Paxlovid and molnupiravir were authorized by the US FDA last week, but supplies of Paxlovid are limited while molnupiravir is less effective than hoped By Melody Schreiber An effective and widely available treatment for Covid would be a significant breakthrough for...
The first-of-its-kind treatment, Paxlovid, has been found to be highly protective against severe illness. It could be available within a few days. By Rebecca Robbins and Carl Zimmer The Food and Drug Administration on Wednesday authorized the first pill for Covid-19,...
The treatment, called Paxlovid, is likely to work against Omicron and could be available in the United States before the end of the year. By Carl Zimmer Pfizer announced on Tuesday that its Covid pill was found to stave off severe disease in a key clinical...
Some laboratory studies suggest that molnupiravir can insert errors in DNA, which could in theory harm a developing fetus, sperm cells or children. By Benjamin Mueller A new Covid-19 pill from Merck has raised hopes that it could transform the landscape of...
By Megan Redshaw A panel of experts advising the U.S. Food and Drug Administration (FDA) on Tuesday voted to recommend Merck’s experimental antiviral pill used to treat COVID-19 for emergency use authorization — overlooking concerns expressed by...